Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer.

Item

http://www.wikidata.org/entity/Q43518078

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Correlation between overall su ...... with advanced gastric cancer.

@en

Correlation between overall su ...... with advanced gastric cancer.

@nl

type

Item

label

Correlation between overall su ...... with advanced gastric cancer.

@en

Correlation between overall su ...... with advanced gastric cancer.

@nl

prefLabel

Correlation between overall su ...... with advanced gastric cancer.

@en

Correlation between overall su ...... with advanced gastric cancer.

@nl

P1476

Correlation between overall su ...... with advanced gastric cancer.

@en

P2093

Atsushi Ohtsu

http://www.w3.org/2001/XMLSchema#string

Kei Muro

http://www.w3.org/2001/XMLSchema#string

Kohei Shitara

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

P2888

s10120-013-0274-6

P304

362-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-013-0274-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Keitaro Matsuo

Toshihiko Doi

P577

2013-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237056789

http://www.w3.org/2001/XMLSchema#string

P698

23736742

http://www.w3.org/2001/XMLSchema#string